Tekgül S, Ozen H, Ozyavuz R, Bakkaloğlu M, Remzi D
Department of Urology, Hacettepe University, School of Medicine, Ankara, Turkey.
Int Urol Nephrol. 1995;27(1):87-91. doi: 10.1007/BF02575225.
We report a total of 169 serial bone scan studies conducted in 21 patients with histologically proven metastatic cancer of the prostate. Aim of the study was to investigate the concordance of findings on bone scans with serum acid phosphate (AP) levels and the clinical performance status (CPS) of the patients, and to see how important bone scan is by itself in determining the metastatic progression in the follow-up. Eighty-seven and 86% of scans demonstrated changes concordant with AP and CPS levels subsequently. It was also found that 100% of the progressions on bone scans along with elevated levels of AP had been confirmed as metastatic progression, whereas only 41% of progressions on bone scans solely had been shown to be metastases in the follow-up investigations. Findings on bone scans not in correlation with clinical findings and serum AP levels are mostly misleading. Use of bone scans in conjunction with serum AP levels and most probably with prostate-specific antigen and CPS is the most reliable and therefore treatment modality changes should not be based on bone scans only.
我们报告了对21例经组织学证实为前列腺转移性癌患者进行的总共169次连续骨扫描研究。本研究的目的是调查骨扫描结果与血清酸性磷酸酶（AP）水平及患者临床性能状态（CPS）之间的一致性，并观察骨扫描本身在确定随访中转移进展方面的重要性。随后，87%和86%的扫描显示出与AP和CPS水平一致的变化。还发现，骨扫描上100%的进展以及AP水平升高已被确认为转移进展，而在后续调查中，仅骨扫描上41%的进展被证明是转移。与临床发现和血清AP水平不相关的骨扫描结果大多具有误导性。将骨扫描与血清AP水平以及很可能与前列腺特异性抗原和CPS结合使用是最可靠的，因此治疗方式的改变不应仅基于骨扫描。
